198 related articles for article (PubMed ID: 37322531)
21. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients.
Vuletić A; Jurišić V; Jovanić I; Milovanović Z; Nikolić S; Konjević G
J Surg Res; 2013 Aug; 183(2):860-8. PubMed ID: 23522458
[TBL] [Abstract][Full Text] [Related]
22. Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study.
Lee GH; An HJ; Kim TH; Kim G; Park KS; Park H; Lee TH; Kwon AY
Yonsei Med J; 2021 Apr; 62(4):288-297. PubMed ID: 33779082
[TBL] [Abstract][Full Text] [Related]
23. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.
Li WX; Pan HF; Hu JL; Wang CZ; Zhang N; Li J; Li XP; Xu JH; Ye DQ
Clin Rheumatol; 2010 Mar; 29(3):315-23. PubMed ID: 20012119
[TBL] [Abstract][Full Text] [Related]
24. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
Bayigga L; Nabatanzi R; Sekiziyivu PN; Mayanja-Kizza H; Kamya MR; Kambugu A; Olobo J; Kiragga A; Kirimunda S; Joloba M; Nakanjako D
BMC Immunol; 2014 Jan; 15():2. PubMed ID: 24483185
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
[TBL] [Abstract][Full Text] [Related]
26. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
[TBL] [Abstract][Full Text] [Related]
27. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.
Gubbels JA; Felder M; Horibata S; Belisle JA; Kapur A; Holden H; Petrie S; Migneault M; Rancourt C; Connor JP; Patankar MS
Mol Cancer; 2010 Jan; 9():11. PubMed ID: 20089172
[TBL] [Abstract][Full Text] [Related]
28. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
29. Tumor infiltrating NK cell (TINK) subsets and functional molecules in patients with breast cancer.
Rezaeifard S; Talei A; Shariat M; Erfani N
Mol Immunol; 2021 Aug; 136():161-167. PubMed ID: 34171565
[TBL] [Abstract][Full Text] [Related]
30. Selective downregulation of natural killer activating receptors on NK cells and upregulation of PD-1 expression on T cells in children with severe and/or recurrent Herpes simplex virus infections.
Lenart M; Kluczewska A; Szaflarska A; Rutkowska-Zapała M; Wąsik M; Ziemiańska-Pięta A; Kobylarz K; Pituch-Noworolska A; Siedlar M
Immunobiology; 2021 May; 226(3):152097. PubMed ID: 34015527
[TBL] [Abstract][Full Text] [Related]
31. Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection.
Miyagi T; Shimizu S; Tatsumi T; Nishio K; Hiramatsu N; Kanto T; Hayashi N; Takehara T
J Gastroenterol; 2011 Aug; 46(8):1020-30. PubMed ID: 21559771
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
33. Low-frequency, exhausted immune status of CD56
Pan Z; Zhao R; Shen Y; Liu K; Xue W; Liang C; Peng M; Hu P; Chen M; Xu H
Int Immunopharmacol; 2021 Dec; 101(Pt B):108369. PubMed ID: 34844872
[TBL] [Abstract][Full Text] [Related]
34. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
35. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
36. Increased Peripheral NKG2A-NKG2D+CD3-CD16+CD56dim NK Cell Subset Was Positively Correlated with Antiphospholipid Antibodies in Patients of Obstetric Antiphospholipid Syndrome.
Zhang Y; Zhao Y; Si W; Yang B; Lin M; Zheng J; Cui L
Immunol Invest; 2022 Feb; 51(2):425-437. PubMed ID: 33103514
[TBL] [Abstract][Full Text] [Related]
37. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
38. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
39. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
40. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
